DK1129186T3 - Et faktor VIII-polypeptid med faktor VIII:C-aktivitet - Google Patents

Et faktor VIII-polypeptid med faktor VIII:C-aktivitet

Info

Publication number
DK1129186T3
DK1129186T3 DK99953425T DK99953425T DK1129186T3 DK 1129186 T3 DK1129186 T3 DK 1129186T3 DK 99953425 T DK99953425 T DK 99953425T DK 99953425 T DK99953425 T DK 99953425T DK 1129186 T3 DK1129186 T3 DK 1129186T3
Authority
DK
Denmark
Prior art keywords
factor viii
activity
polypeptide
fviii
domains
Prior art date
Application number
DK99953425T
Other languages
English (en)
Other versions
DK1129186T4 (da
Inventor
Koenraad Mertens
Peter Turecek
Hans-Peter Schwarz
Friedrich Scheiflinger
Petrus Johannes Lenting
Mourik Jan Aart Van
Hans Pannekoek
Original Assignee
Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3522842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1129186(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanquin Bloedvoorziening filed Critical Sanquin Bloedvoorziening
Publication of DK1129186T3 publication Critical patent/DK1129186T3/da
Application granted granted Critical
Publication of DK1129186T4 publication Critical patent/DK1129186T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99953425.8T 1998-11-10 1999-11-10 Et faktor VIII-polypeptid med faktor VIII:C-aktivitet DK1129186T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT187298 1998-11-10
PCT/AT1999/000272 WO2000028021A1 (de) 1998-11-10 1999-11-10 Ein faktor viii-polypeptid mit faktor viii:c-aktivität

Publications (2)

Publication Number Publication Date
DK1129186T3 true DK1129186T3 (da) 2008-01-21
DK1129186T4 DK1129186T4 (da) 2017-02-06

Family

ID=3522842

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99953425.8T DK1129186T4 (da) 1998-11-10 1999-11-10 Et faktor VIII-polypeptid med faktor VIII:C-aktivitet

Country Status (11)

Country Link
US (3) US6919311B2 (da)
EP (1) EP1129186B2 (da)
AT (1) ATE372382T1 (da)
AU (2) AU775529B2 (da)
CA (1) CA2349468C (da)
CY (1) CY1107821T1 (da)
DE (1) DE59914490D1 (da)
DK (1) DK1129186T4 (da)
ES (1) ES2292255T5 (da)
PT (1) PT1129186E (da)
WO (1) WO2000028021A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129186B2 (de) * 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
WO2000071714A2 (en) * 1999-05-24 2000-11-30 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
DE60332011D1 (de) * 2002-04-29 2010-05-20 Sanquin Bloedvoorziening Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein")
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1985631A1 (en) * 2007-04-20 2008-10-29 LFB Biotechnologies Demannosylated recombinant factor VIII for the treatment of patients with hemophiila A
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
EP2616486B1 (en) 2010-09-15 2019-01-02 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake
CA2810731A1 (en) 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph
BRPI1105317A2 (pt) * 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015073418A2 (en) * 2013-11-15 2015-05-21 President And Fellows Of Harvard College Methods and assays for factor viii activity
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
EP3283108B1 (en) 2015-04-13 2020-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA3007364A1 (en) 2015-12-03 2017-06-08 Baxalta Incorporated Factor viii with extended half-life and reduced ligand-binding properties
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) † 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
WO1997003195A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
EP1129186B2 (de) * 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität

Also Published As

Publication number Publication date
EP1129186A1 (de) 2001-09-05
AU775529B2 (en) 2004-08-05
ATE372382T1 (de) 2007-09-15
WO2000028021A1 (de) 2000-05-18
US20050074836A1 (en) 2005-04-07
US6919311B2 (en) 2005-07-19
AU1018500A (en) 2000-05-29
DE59914490D1 (de) 2007-10-18
EP1129186B2 (de) 2016-11-30
US8546332B2 (en) 2013-10-01
US20110118188A1 (en) 2011-05-19
CA2349468A1 (en) 2000-05-18
ES2292255T3 (es) 2008-03-01
AU2004222822A1 (en) 2004-11-18
US7544660B2 (en) 2009-06-09
CY1107821T1 (el) 2013-06-19
AU2004222822B2 (en) 2007-01-25
US20060160994A1 (en) 2006-07-20
ES2292255T5 (es) 2017-05-19
DK1129186T4 (da) 2017-02-06
PT1129186E (pt) 2007-12-07
CA2349468C (en) 2013-07-09
EP1129186B1 (de) 2007-09-05

Similar Documents

Publication Publication Date Title
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
EP1137941A4 (en) PROTEIN SCAFFOLDS FOR ANTIBODY MIMES AND OTHER BINDING PROTEINS
HRP20000714B1 (en) NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
DK0503648T3 (da) CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3
US5043429B1 (en) Protein fragments containing factor VIII binding domain of von willebrand factor
NO982550L (no) 1L-13 reseptor polypeptid
DE68917323D1 (de) Expressions-Vektor für Fusions-Proteine und Immunogen-Proteine.
FI954805A0 (fi) Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
FI972384L (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-terminaalisia sulfonyyli- tai amidinosulfonyyliryhmiä
ATE225806T1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
NO922421D0 (no) Collagenbindende protein, samt fremstilling derav
ATE356831T1 (de) Neuer galaninrezeptor
DE3852293D1 (de) Verfahren und struktur zur justierung von reflektorflächen.
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
EP0588036A3 (en) Composition for the isolation of apamine receptor, apamine binding protein and its uses.
FI891652A7 (fi) Menetelmä proteiinien valmistamiseksi, joiden N-terminaali alkaa proliinilla
ATA110696A (de) Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
BR0011802A (pt) Proteìna citoplasmática de ligação de cálcio induzida por trauma de cabeça
SE9604439D0 (sv) New receptor